



## **Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023**

February 28, 2023

HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update.

Register for the live webcast using the link [here](#) or by visiting the "Investors" section of the Alaunos website at [www.alaunos.com](http://www.alaunos.com). To participate via telephone, please register in advance at this [link](#). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The event will be archived on the Company's website for approximately 30 days after the call.

### **About Alaunos Therapeutics, Inc.**

Alaunos Therapeutics is a leader in the science of T-cell receptor (TCR) cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company's TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral *Sleeping Beauty* cell engineering platform; and its hunTR<sup>®</sup> discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit [www.alaunos.com](http://www.alaunos.com).

### **Investor Relations Contact:**

Alex Lobo  
Stern Investor Relations  
[Alex.lobos@sternir.com](mailto:Alex.lobos@sternir.com)

### **Media Contact:**

Heather Anderson  
6 Degrees PR  
[handerson@6degreespr.com](mailto:handerson@6degreespr.com)